Cilostazol
Cilostazol (cilostazol) is a small molecule pharmaceutical. Cilostazol was first approved as Pletal on 1999-01-15. It is used to treat intermittent claudication, peripheral vascular diseases, and vascular graft occlusion in the USA. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B. In addition, it is known to target cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Cilostazol (discontinued: Cilostazol, Pletal)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cilostazol | ANDA | 2025-01-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| intermittent claudication | EFO_0003876 | D007383 | I73.9 |
| peripheral vascular diseases | EFO_0003875 | D016491 | I73.9 |
| vascular graft occlusion | — | D006083 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
171 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral infarction | D002544 | — | I63 | — | — | 1 | 2 | — | 3 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 1 | 2 | — | 3 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | 1 | — | 2 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | — | — | 2 | — | 2 |
| Cerebral small vessel diseases | D059345 | — | — | — | — | — | 1 | — | 1 |
| Coronary disease | D003327 | — | — | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 1 | — | 1 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cilostazol |
| INN | cilostazol |
| Description | Cilostazol is a lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substituted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group. It has a role as a bronchodilator agent, a vasodilator agent, a fibrin modulating drug, a platelet aggregation inhibitor, a neuroprotective agent, an anticoagulant and an EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor. It is a member of tetrazoles and a lactam. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1 |
Identifiers
| PDB | — |
| CAS-ID | 73963-72-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL799 |
| ChEBI ID | 31401 |
| PubChem CID | 2754 |
| DrugBank | DB01166 |
| UNII ID | N7Z035406B (ChemIDplus, GSRS) |
Target
Agency Approved
PDE3B
PDE3B
Organism
Homo sapiens
Gene name
PDE3B
Gene synonyms
NCBI Gene ID
Protein name
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
Protein synonyms
CGI-PDE B, CGIP1, CGIPDE1, cGMP-inhibited 3',5'-cyclic phosphodiesterase B, Cyclic GMP-inhibited phosphodiesterase B, cyclic nucleotide phosphodiesterase, phosphodiesterase 3B, cGMP-inhibited
Uniprot ID
Mouse ortholog
Pde3b (18576)
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B (Q9Z1J9)
Alternate
PDE3A
PDE3A
Organism
Homo sapiens
Gene name
PDE3A
Gene synonyms
NCBI Gene ID
Protein name
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Protein synonyms
cAMP phosphodiesterase, myocardial cGMP-inhibited, cGI-PDE, CGI-PDE A, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, cGMP-inhibited cAMP phosphodiesterase, Cyclic GMP-inhibited phosphodiesterase A, phosphodiesterase 3A, cGMP-inhibited
Uniprot ID
Mouse ortholog
Pde3a (54611)
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (Q9Z0X4)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Cilostazol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,465 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cilostazol
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,383 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use